Compare · BRLI vs CCXI
BRLI vs CCXI
Side-by-side comparison of Brilliant Acquisition Corporation (BRLI) and Churchill Capital Corp XI (CCXI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BRLI and CCXI operate in Blank Checks (Finance), so they compete in similar markets.
- CCXI has hit the wire 49 times in the past 4 weeks while BRLI has been quiet.
- CCXI has more recent analyst coverage (8 ratings vs 0 for BRLI).
Brilliant Acquisition Corporation
Brilliant Acquisition Corporation operates as a blank check company. It focuses on acquiring; engaging in share exchange and share reconstruction; purchasing the assets; entering into contractual arrangements; and engaging in similar business combination with one or more businesses. The company was founded in 2019 and is based in Shanghai, China.
Churchill Capital Corp XI
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It develops Avacopan, an orally administered selective complement 5a receptor inhibitor for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis; and completed Phase II clinical trial for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. The company is also developing CCX559, an orally-administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally-administered inhibitor of the chemokine receptor CC9, which has completed Phase I clinical trial or the treatment of inflammatory bowel disease. In addition, it develops CCX587 for the treatment of TH17 driven diseases. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in Mountain View, California.
Latest BRLI
- SEC Form SC 13G filed by Brilliant Acquisition Corporation
- Brilliant Acquisition Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Brilliant Acquisition Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Brilliant Acquisition Corporation filed SEC Form 8-K: Other Events
- Brilliant Acquisition Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Change in Shell Company Status, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure
- SEC Form NT 10-K filed by Brilliant Acquisition Corporation
- SEC Form 25-NSE filed by Brilliant Acquisition Corporation
- Nukkleus Inc. Closes Merger with Brilliant Acquisition Corporation
- Brilliant Acquisition Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure
- Brilliant Acquisition Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Latest CCXI
- Chief Operating Officer Hunter Jennifer was granted 3,220,699 stock options (SEC Form 4)
- Officer Lang Anastasia was granted 2,760,599 stock options (SEC Form 4)
- Director Shelton Damion was granted 9,938,151 shares (SEC Form 4)
- Chief Technology Officer Velagapudi Prasanna was granted 3,680,797 stock options (SEC Form 4)
- Chief Financial Officer Beer Michael Thomas was granted 2,576,560 shares (SEC Form 4)
- Chief Executive Officer Johnson Margaret L was granted 347,790 shares (SEC Form 4)
- Chief Robot Officer Hurst Jonathan was granted 12,422,709 shares (SEC Form 4)
- Chief Hardware Officer Marroquin Marco was granted 2,300,498 stock options (SEC Form 4)
- President Diez Daniel was granted 3,220,699 stock options (SEC Form 4)
- SEC Form 3 filed by new insider Hunter Jennifer